Prognostic significance of p21WAF1/CIP1, p16INK4a and CD44s in tongue cancer

Oncology Reports

Volumn 18, Issue 2, 2007, Pages 389-396

  González Moles, Miguel Angel ^a   Gil Montoya, J A ^a   Ruiz Avila, I ^b   Esteban, F ^c   Delgado Rodriguez, M ^d   Bascones Martinez, A ^e  

^a UNIVERSITY OF GRANADA   (Spain)

^b Pathology Department   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d UNIVERSITY OF JAÉN   (Spain)

^e UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

CD44; Oral cancer; Recurrence; Survival; Tongue cancer

Indexed keywords

CD44 PROTEIN, HUMAN; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; HERMES ANTIGEN; PROTEIN P16INK4A; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHEMISTRY; EPITHELIUM; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; SURVIVAL; SURVIVAL RATE; TONGUE TUMOR; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD44; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; EPITHELIUM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SURVIVAL ANALYSIS; SURVIVAL RATE; TONGUE NEOPLASMS;

EID: 34548538552     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.18.2.389     Document Type: Article

References (58)

1. Lundberg AS and Weinberg RA: Control of the cell cycle and apoptosis. Eur J Cancer 35: 1886-1884, 1999.
2. Todd R, Hinds PW, Munger K, et al: Cell cycle dysregulation in oral cancer. Crit Rev Oral Biol Med 13: 51-61, 2002. (Pubitemid 34792760)
3. Nevins JR: E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science 258: 424-429, 1992.
4. Loughran O, Owens D, Gallimore PH, et al: Association of CDKN2A/p16INK4a with human head and neck keratinocyte replicative senescence: relationship of dysfunction to immortality and neoplasia. Oncogene 13: 561-568, 1996. (Pubitemid 26283852)
5. Papadimitrakopoulo V, Izzo J, Lippman SM, et al: Frequent inactivation of p16INK4a in oral premalignant lesions. Oncogene 14: 1799-1803, 1997. (Pubitemid 27207680)
6. Rocco JW, Li D, Ligget WH, et al: p16INK4A adenovirus-mediated gene therapy for human head and neck squamous cell cancer. Clin Cancer Res 4: 1697-1704, 1998. (Pubitemid 28304731)
7. Timmermann S, Hinds PW and Munger K: Re-expression of endogenous p16ink4a in oral squamous cell carcinoma lines by 5-aza-2′-deoxycytidine treatment induces a senescence-like state. Oncogene 17: 3445-3453, 1998. (Pubitemid 29050679)
8. Chen Q, Lue G, Li B and Samaranayake LP: Expression of p16 and CDK4 in oral premalignant lesions and oral squamous cell carcinomas: a semi-quantitative immunohistochemical study. J Oral Pathol Med 28: 158-164, 1999. (Pubitemid 29174802)
9. Bova RJ, Quinn DI, Nankervis JS, et al: Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue. Clin Cancer Res 5: 2810-2819, 1999. (Pubitemid 29493956)
10. Danahey DG, Tobin EJ, Schuller DE, Bier-Laning CM, Webhorst CM and Lang JC: p16 mutation frequency and clinical correlation in head and neck cancer. Acta Otolaryngol 119: 285-288, 1999. (Pubitemid 29177085)
11. Weinberger PM, Yu Z, Haffty BG, et al: Prognosis significance of p16 protein levels in oropharyngeal squamous cell cancer. Clin Cancer Res 10: 5684-5691, 2004. (Pubitemid 39180943)
12. Gonzalez-Moles MA, Esteban F, Bravo-Perez JJ, et al: Adhesion molecule CD44 expression in non-tumor epithelium adjacent to laryngeal cancer. Onkologie 29: 9-13, 2006. (Pubitemid 43339690)
13. Chang KW, Lin SC, Kwan PC and Wong YK: Association of aberrant p53 and p21waf1/cip1(WAF1) immunoreactivity with the outcome of oral verrucous leukoplakia in Taiwan. J Oral Pathol Med 29: 56-62, 2000.
14. Frank JL, Bur ME, Garb JL, Kay S, Ware JL, Sismanis A, et al:p53 tumor suppressor oncogene expression in squamous cell carcinoma of the hypopharynx. Cancer 73: 181-186, 1994.
15. Agarwal S, Mathur M, Shukla NK and Ralhan R: Expression of cyclin dependent kinase inhibitor p21waf1/cip1waf1/cip1 in premalignant and malignant oral lesions: relationship with p53 status. Oral Oncol 34: 353-360, 1998. (Pubitemid 28440296)
16. Kudo Y, Takata T, Ogawa I, Sato S and Nikai H: Expression of p53 and p21waf1/cip1CIP1/WAF1 proteins in oral epithelial dysplasias and squamous cell carcinomas. Oncol Rep 6: 539-545, 1999.
17. Gonzalez-Moles MA, Ruiz-Avila I, Fernandez-Martinez JA, et al: P21WAF1/CIP1 protein and tongue cancer prognosis. Anticancer Res 24: 3225-3232, 2004.
18. Yuen PW, Chow V, Choy J, Lam KY, Ho WK and Wei WI: The clinicopathologic significance of p53 and p21waf1/cip1 expression in the surgical management of lingual squamous cell carcinoma. Am J Clin Pathol 116: 240-245, 2001. (Pubitemid 33044329)
19. Xie X, Clausen OP and Boysen M: Prognostic significance of p21waf1/cip1WAF1/CIP1 expression in tongue squamous cell carcinomas. Arch Otolaryngol Head Neck Surg 128: 897-902, 2002. (Pubitemid 34856258)
20. Spandidos DA, Lamothe A and Field JK: Multiple transcriptional activation of cellular oncogenes in human head and neck solid tumours. Anticancer Res 5: 221-224, 1985.
21. Pande P, Soni S, Kaur J, et al: Prognostic factors in betel and tobacco related oral cancer. Oral Oncol 38: 491-499, 2000.
22. Tatemoto Y, Osaki T, Yoneda K, Yamamoto T, Ueta E and Kimura T: Expression of p53 and p21waf1/cip1 proteins in oral squamous cell carcinoma: correlation with lymph node metastasis and response to chemoradiotherapy. Pathol Res Pract 194: 821-830, 1998. (Pubitemid 29012243)
23. Kapranos N, Stathopoulos GP, Manolopoulos L, et al: p53, p21waf1/cip1 and p27 protein expression in head and neck cancer and their prognostic value. Anticancer Res 21: 521-528, 2001. (Pubitemid 32267565)
24. Tsuji T, Sasaki K and Shinozaki F: An expression of squamous cell carcinoma-related antigen in oral cancers. Int J Oral Maxillofac Surg 18: 241-243, 1989. (Pubitemid 19241143)
25. Bryne M: Is the invasive front of an oral carcinoma the most important area for prognostication? Oral Dis 4: 70-77, 1998.
26. Mori S, Nose M, Morikawa H, et al: A novel evaluation system of metastatic potential of oral squamous cell carcinoma according to the histopathological and histochemical grading. Oral Oncol 34: 549-557, 1998. (Pubitemid 28546873)
27. Borland G, Ross JA and Guy K: Forms and functions of CD44. Immunology 93: 139-148, 1998. (Pubitemid 28088279)
28. Mackay CR, Terpe HJ, Stauder R, Marston WL, Stark H and Gunthert U: Expression and modulation of CD44 variant isoforms in humans. J Cell Biol 124: 71-82, 1994. (Pubitemid 24054611)
29. Gonzalez-Moles MA, Bravo M, Ruiz-Avila I, Esteban F, Bascones-Martinez A and Gonzalez-Moles S: Adhesion molecule CD44 expression in non-tumour epithelium adjacent to tongue cancer. Oral Oncol 40: 281-286, 2004. (Pubitemid 38121565)
30. Esteban F, Bravo JJ, Gonzalez-Moles MA, Ruiz-Avila I, Bravo M and Gil-Montoya JA: Adhesion molecule CD44 as a prognosis factor in laryngeal cancer. Anticancer Res 25: 1115-1122, 2005.
31. Spiessl B: International union against cancer. In: TNM Atlas Illustrated Guide to the TNM, pTNM Classification of Malignant Tumors. 3rd edition, 2nd rev. Springer-Verlag, Berlin, New York, 1992.
32. Gonzalez-Moles MA, Esteban F, Rodriguez-Archilla A, Ruiz-Avila I and Gonzalez-Moles S: Importance of tumour thickness measurement in prognosis of tongue cancer. Oral Oncol 38: 394-397, 2002. (Pubitemid 34655696)
33. Stoll C, Baretton G, Soost F, Terpe, Domide P and Lohrs U: Prognostic importance of the expression of CD44 splice variants in oral squamous cell carcinomas. Oral Oncol 35: 484-489, 1999. (Pubitemid 29386784)
34. Hirvikoski P, Tammi R, Kumpulainen E, et al: Irregular expression of hyaluronan and its CD44 receptor is associated with metastatic phenotype in laryngeal squamous cell carcinoma. Virchows Arch 434: 37-44, 1999. (Pubitemid 29184900)
35. Kanke M, Fujii M, Kameyama K, et al: Role of CD44 variant exon 6 in invasion of head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 126: 1217-1223, 2000.
36. Fonseca I, Pereira T, Rosa-Santos J and Soares J: Expression of CD44 isoforms in squamous cell carcinoma of the border of the tongue: a correlation with histological grade, pattern of stromal invasion, and cell differentiation. J Surg Oncol 76: 115-120, 2001.
37. Sato S, Miyauchi M, Takekoshi T, et al: Reduced expression of CD44 variant 9 is related to lymph node metastasis and poor survival in squamous cell carcinoma of tongue. Oral Oncol 36: 545-549, 2000.
38. Rothman KJ and Greenland S: Modern Epidemiology. 2nd edition. Lippincott-Raven, Boston, 1997.
39. Sun GW, Shook TL and Kay GL: Inappropriate use of bivariable analysis to screen risk factors for use in multivariate analysis. J Clin Epidemiol 49: 907-916, 1996. (Pubitemid 26283404)
40. Barnes L, Eveson JW, Reichart P and Sidransky D (eds): Pathology and Genetics. Head and neck tumours. In: World Heatlh Organization Classification of Tumours. IARC Press, Lyon, 2005.
41. Sato S, Miyauchi M, Kato M, et al: Upregulated CD44v9 expression inhibits the invasion of oral squamous cell carcinoma cells. Pathobiology 71: 171-175, 2004. (Pubitemid 38969874)
42. Sato S, Miyauchi M, Ogawa I, et al: Inhibition of CD44v9 upregulates the invasion ability of oral squamous cell carcinoma cells. Oral Oncol 39: 27-30, 2003. (Pubitemid 35379815)
43. Bankfalvi A, Krassort M, Buchwalow IB, Vegh A, Felszeghy E and Piffko J: Gains and losses of adhesion molecules (CD44, E-cadherin, and beta-catenin) during oral carcinogenesis and tumour progression. J Pathol 198: 343-351, 2002. (Pubitemid 35277385)
44. Ogawa A, Fukuta Y, Nakajima T, et al: Treatment results of oral verrucous carcinoma and its biological behavior. Oral Oncol 40: 793-797, 2004. (Pubitemid 39061094)
45. Yuen PW, Man M, Lam KY and Kwong YL: Clinicopathological significance of p16 gene expression in the surgical treatment of head and neck squamous cell carcinomas. J Clin Pathol 55: 58-60, 2002. (Pubitemid 34081683)
46. Geisler SA, Olshan AF, Weissler MC, et al: p16 and p53 protein expression as prognostic indicators of survival and disease recurrence from head and neck cancer. Clin Cancer Res 8: 3445-3453, 2002. (Pubitemid 35340720)
47. Chin D, Boyle GM, Williams RM, et al: Novel markers for poor prognosis in head and neck cancer. Int J Cancer 113: 789-797, 2005. (Pubitemid 40101261)
48. Taylor D, Koch WM, Zahurak M, Shah K, Sidransky D and Westra WH: Immunohistochemical detection of p53 protein accumulation in head and neck cancer: correlation with p53 gene alterations. Hum Pathol 30: 1221-1225, 1999. (Pubitemid 29480892)
49. Muirhead DM, Hoffman HT and Robinson RA: Correlation of clinicopathologic features with immunohistochemical expression of cell cycle regulatory proteins p16 and Rb: Distinct association with keratinization and differentiation in oral cavity squamous cell carcinoma. J Clin Pathol 59: 711-715, 2006. (Pubitemid 44048779)
50. Soni S, Kaur J, Kumar A, et al: Alterations of rb pathway components are frequent events in patients with oral epithelial dysplasia and predict clinical outcome in patients with squamous cell carcinoma. Oncology 68: 314-325, 2005. (Pubitemid 41160959)
51. Ralhan R, Chakravarti N, Kaur J, et al: Clinical significance of altered expression of retinoid receptors in oral precancerous and cancerous lesions: relationship with cell cycle regulators. Int J Cancer 118: 1077-1089, 2006. (Pubitemid 43185593)
52. Gonzalez-Moles MA, Rodriguez-Archilla A, Ruiz-Avila I, Martinez AB, Morales-Garcia P and Gonzalez-Moles S: p16 expression in squamous carcinomas of the tongue. Onkologie 25: 433-436, 2002. (Pubitemid 36160182)
53. Klussmann JP, Gultekin E, Weissenborn SJ, et al: Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. Am J Pathol 162: 747-753, 2003. (Pubitemid 36237483)
54. Gonzalez-Moles MA, Bravo M, Ruiz-Avila I, Esteban F, et al:Adhesion molecule CD44 as a prognostic factor in tongue cancer. Anticancer Res 23: 5197-5102, 2003.
55. Spafford MF, Koeppe J, Pan Z, Archer PG, Meyers AD and Franklin WA: Correlation of tumor markers p53, bcl-2, CD34, CD44H, CD44v6, and Ki-67 with survival and metastasis in laryngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 122: 627-632, 1996. (Pubitemid 26178794)
56. Braakhuis B, Tabor M, Leemans CR, van der Waal I, Snow GB and Brakenhoff RH: Second primary tumors and field cancerization in oral and oropharyngeal cancer: molecular techniques provide new insights and definitions. Head Neck 24: 198-206, 2002. (Pubitemid 34111517)
57. Califano J, van der Riet P, Westra W, et al: Genetic progression model for head and neck cancer: Implications for field cancerization. Cancer Res 56: 2488-2492, 1996. (Pubitemid 26170679)
58. Tabor MP, Brakenhoff RH, van Houten VMM, et al:Persistence of genetically altered fields in head and neck cancer patients: biological and clinical implications. Clin Cancer Res 7: 1523-1532, 2001. (Pubitemid 32708615)